Supporting the Lung and Resolving Toxins Prescription in the Treatment of Advanced Non-small Cell Lung Cancer with Yin Deficiency and Toxin-heat Syndrome

Key Points

• The study evaluates the clinical efficacy and safety of a traditional Chinese medicine intervention in treating advanced NSCLC with specific syndromes.
• 50 patients with stage IIIB-IV non-small cell lung cancer were randomly assigned to treatment and control groups.
• The treatment group received immune checkpoint inhibitors alongside traditional therapy for four 21-day cycles.
• Comparisons were made on clinical efficacy, quality of life scores, and adverse reactions.
• The treatment group showed superior objective response rates and disease control rates compared to the control group (P<0.05).
• Karnofsky performance status scores improved and syndrome scores decreased significantly in the treatment group (P<0.05).
• Adverse reactions such as rash and liver damage were lower in the treatment group (P<0.05).